This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The conversation delves into various educational resources utilized both by healthcare providers and patients regarding ddalimumab biosimilars. Providers emphasize the importance of authoritative sources such as the FDA and professional societies like the American College of Rheumatology for accurate information on interchangeability and biosimilars.

While some providers note a lack of comprehensive resources, they highlight the American Academy of Dermatology and New Zealand DermNet as useful references. Patient education materials from organizations like the Crohn's and Colitis Foundation are also recommended.

Providers stress the need for proactive patient engagement and filtering information from reliable sources, discouraging reliance on social media or blogs for medical advice. To ensure patient understanding, nurses play a crucial role in creating educational tools and facilitating communication, including preemptive notifications about changes in medication availability.

Overall, the discussion underscores the importance of ongoing education and communication between healthcare providers and patients to optimize treatment outcomes with Adalimumab biosimilars.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.